Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: A microdialysis study

Journal of Neuro-Oncology

Volumn 91, Issue 1, 2009, Pages 51-58

  Blakeley, Jaishri O ^a   Olson, Jeffrey ^b   Grossman, Stuart A ^a   He, Xiaoying ^c   Weingart, Jon ^a   Supko, Jeffrey G ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Drug delivery; Glioma; Microdialysis; Pharmacokinetics

Indexed keywords

METHOTREXATE;

ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; CANCER GRADING; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; GLIOMA; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MICRODIALYSIS; PERMEABILITY BARRIER;

ADULT; AGED; AREA UNDER CURVE; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GLIOMA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; MASS SPECTROMETRY; METHOTREXATE; MICRODIALYSIS; MIDDLE AGED; TIME FACTORS;

EID: 57049117489     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9678-2     Document Type: Article

References (35)

1. Butowski NA, Sneed PK, Chang SM (2006) Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol 24(8):1273-1280. doi: 10.1200/JCO.2005.04.7522
2. Stupp R, Hegi ME, Gilbert MR et al (2007) Chemoradiotherapy in malignant glioma: Standard of care and future directions. J Clin Oncol 25(26):4127-4136. doi: 10.1200/JCO.2007.11.8554
3. Reardon DA, Rich JN, Friedman HS et al (2006) Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 24(8):1253-1265. doi: 10.1200/JCO.2005.04.5302
4. Brandsma Dvan den Bent MJ (2007) Molecular targeted therapies and chemotherapy in malignant gliomas. Curr Opin Oncol 19(6):598-605
5. Omuro AM, Faivre S, Raymond E (2007) Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 6(7):1909-1919. doi: 10.1158/1535-7163.MCT-07-0047
6. Jain RK (1994) Barriers to drug delivery in solid tumors. Sci Am 271(1):58-65
7. Netti PA, Baxter LT, Boucher Y et al (1995) Time-dependent behavior of interstitial fluid pressure in solid tumors: Implications for drug delivery. Cancer Res 55(22):5451-5458
8. Neuwelt EA (2004) Mechanisms of disease: The blood-brain barrier. Neurosurgery 54(1):131-140. doi: 10.1227/01.NEU.0000097715.11966.8E discussion 141-2
9. Motl S, Zhuang Y, Waters CM et al (2006) Pharmacokinetic considerations in the treatment of CNS tumours. Clin Pharmacokinet 45(9):871-903. doi: 10.2165/00003088-200645090-00002
10. Doolittle ND, Peereboom DM, Christoforidis GA et al (2007) Delivery of chemotherapy and antibodies across the blood-brain-barrier and the role of chemoprotection, in primary and metastatic brain tumors: Report of the eleventh annual blood-brain barrier consortium meeting. J Neurooncol 81(1):81-91. doi: 10.1007/s11060-006-9209-y
11. Muldoon LL, Soussain C, Jahnke K et al (2007) Chemotherapy delivery issues in central nervous system malignancy: A reality check. J Clin Oncol 25(16):2295-2305. doi: 10.1200/JCO.2006.09.9861
12. Nicolazzo JA, Charman SA, Charman WN (2006) Methods to assess drug permeability across the blood-brain barrier. J Pharm Pharmacol 58(3):281-293. doi: 10.1211/jpp.58.3.0001
13. de Lange EC, Danhof M, de Boer AG et al (1997) Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier. Brain Res Brain Res Rev 25(1):27-49. doi: 10.1016/S0165-0173(97)00014-3
14. de Lange EC, Danhof M (2002) Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: Implications of the barriers between blood and brain. Clin Pharmacokinet 41(10):691-703. doi: 10.2165/00003088-200241100-00001
15. Perkins AC, Frier M (2004) Radionuclide imaging in drug development. Curr Pharm Des 10(24):2907-2921. doi: 10.2174/1381612043383476
16. Johansen MJ, Newman RA, Madden T (1997) The use of microdialysis in pharmacokinetics and pharmacodynamics. Pharmacotherapy 17(3):464-481
17. Siddiqui MM, Shuaib A (2001) Intracerebral microdialysis and its clinical application: A review. Methods 23(1):83-94. doi: 10.1006/ meth.2000.1108
18. Major O, Shdanova T, Duffek L et al (1990) Continuous monitoring of blood-brain barrier opening to Cr51-EDTA by microdialysis following probe injury. Acta Neurochir Suppl (Wien) 51:46-48
19. Ungerstedt U, Rostami E (2004) Microdialysis in neurointensive care. Curr Pharm Des 10(18):2145-2152. doi: 10.2174/1381612043384105
20. Mindermann T, Zimmerli W, Gratzl O (1998) Rifampin concentrations in various compartments of the human brain: A novel method for determining drug levels in the cerebral extracellular space. Antimicrob Agents Chemother 42(10):2626-2629
21. Bergenheim AT, Capala J, Roslin M et al (2005) Distribution of BPA and metabolic assessment in glioblastoma patients during BNCT treatment: A microdialysis study. J Neurooncol 71(3):287-293. doi: 10.1007/ s11060-004-1724-0
22. de Lange EC, de Vries JD, Zurcher C et al (1995) The use of intracerebral microdialysis for the determination of pharmacokinetic profiles of anticancer drugs in tumor-bearing rat brain. Pharm Res 12(12):1924-1931. doi: 10.1023/A:1016239822287
23. Devineni D, Klein-Szanto A, Gallo JM (1996) In vivo microdialysis to characterize drug transport in brain tumors: Analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats. Cancer Chemother Pharmacol 38(6):499-507. doi: 10.1007/s002800050518
24. Dukic S, Heurtaux T, Kaltenbach ML et al (1999) Pharmacokinetics of methotrexate in the extracellular fluid of brain C6-glioma after intravenous infusion in rats. Pharm Res 16(8):1219-1225. doi: 10.1023/ A:1018945529611
25. Dukic S, Kaltenbach ML, Gourdier B et al (1998) Determination of free extracellular levels of methotrexate by microdialysis in muscle and solid tumor of the rabbit. Pharm Res 15(1):133-138. doi: 10.1023/ A:1011973409022
26. Eder JP Jr, Supko JG, Lynch T et al (1998) Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion. Clin Cancer Res 4(2):317-324
27. Comandone A, Passera R, Boglione A, Tagini V, Ferrari SandCattel L (2005) High dose methotrexate in adult patients with osteosarcoma: Clinical and pharmacokinetic results. Acta Oncol 44:406-411. doi: 10.1080/02841860510029770
28. Earnest FIV, Kelly PJ, Scheithauer BW et al (1988) Cerebral astrocytomas: Histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 166(3):823-827
29. McKnight TR, von dem Bussche MH, Vigneron DB et al (2002) Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 97(4):794-802
30. Donelli MG, Zucchetti M D'Incalci M (1992) Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 30(4):251-260. doi: 10.1007/BF00686291
31. Hesselink JR, Press GA (1988) MR contrast enhancement of intracranial lesions with Gd-DTPA. Radiol Clin North Am 26(4):873-887
32. Flannery T, McConnell RS, McQuaid S et al (2007) Detection of cathepsin S cysteine protease in human brain tumour microdialysates in vivo. Br J Neurosurg 21(2):204-209. doi: 10.1080/02688690701248190
33. Rochas MA, Tufenkji AE, Levillain P et al (1991) Protein binding of methotrexate to human albumin and serum. A first derivative spectroscopic analysis. Arzneimittelforschung 41(12):1286-1288
34. Maia MB, Saivin S, Chatelut E et al (1996) In vitro and in vivo protein binding of methotrexate assessed by microdialysis. Int J Clin Pharmacol Ther 34(8):335-341
35. Wolff JE, Trilling T, Molenkamp G, Egeler RM, Jurgens H (1999) Chemosensitivity of glioma cells in vitro: A metaanalysis. J Cancer Res Clin Oncol 125:481-486